logo

KREBSBIO vs MEDICO: Stock Comparison

KREBS BIOCHEMICALS & IND vs MEDICO REMEDIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

MEDICO REMEDIES is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows a lower P/E, while MEDICO REMEDIES shows faster revenue growth, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KREBSBIO leads 2; MEDICO leads 6 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KREBSBIOMEDICO

Valuation lens

What price are you paying?

Market CapContext only
₹125 Cr
₹169 Cr
P/E RatioKREBSBIO has the lower reading
0x ✓
26.66x
P/B RatioKREBSBIO has the lower reading
0x ✓
4.86x
EPSMEDICO has the higher reading
₹-1.15
₹0.3 ✓
Book ValueContext only
—
₹9.1
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
MEDICO is the larger company
₹169 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 26.66x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 4.86x
EPS
MEDICO has higher earnings per share
₹0.3 vs ₹-1.15
Revenue Growth (TTM YoY)
MEDICO has faster revenue growth
37.5% vs 11.6%
EPS Growth (TTM YoY)
MEDICO has faster EPS growth
36.5% vs 0%
ROCE
MEDICO has a higher ROCE
15.14% vs -15.89%
Net Margin
MEDICO has a higher net margin
6.36% vs -71.35%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOMEDICO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOMEDICO
Live Price₹57.48₹20.5
Day Change2.53%-1.35%
Volume3,57064,951
52-Week High₹76.85₹56.88
52-Week Low₹38.33₹20.47
Distance from 52W High-25.2%-63.96%

Valuation

MetricKREBSBIOMEDICO
Market Cap₹125 Cr₹169 Cr
P/E Ratio0x26.66x
P/B Ratio0x4.86x
EPS₹-1.15₹0.3
Book Value—₹9.1
Dividend Yield0%0%

Growth

MetricKREBSBIOMEDICO
Revenue Growth (TTM YoY)11.6%37.5%
EPS Growth (TTM YoY)0%36.5%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKREBSBIOMEDICO
ROE—17.38%
ROCE-15.89%15.14%
Net Margin-71.35%6.36%
Operating Margin-41.49%9.63%
Debt to Equity—0.25x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKREBSBIOMEDICO
Promoter Holding72.74%61.38%
FII Holding0.5%0.6%▲ 0.52 pp
DII Holding0%0%
Public Holding26.76%38.02%▼ 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and MEDICO REMEDIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.